In this multicenter , open-label , randomized , superiority trial , adult , febrile , high-risk neutropenic patients ( FhrNPs ) with hematologic malignancies were randomly assigned to receive piperacillin/tazobactam ( 4.5 g intravenously every 8 hours ) with or without tigecycline ( 50 mg intravenously every 12 hours ; loading dose 100 mg ) .